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High-risk human papillomaviruses (high-risk HPVs) have been recently reported to be
co-present with Epstein–Barr virus (EBV) in different types of human cancers including
head and neck (HN), where they can cooperate in the initiation and/or progression
of this cancer. Accordingly, we herein explored the prevalence of high-risk HPVs and
EBV in 80 HN cancer tissues from the Syrian population using polymerase chain
reaction, immunohistochemistry, and tissue microarray methodologies. We report that
high-risk HPVs and EBV are present in 35/80 (43.7%) and 41/80 (51.2%) of our
samples, respectively, and the most frequent HPV types are 33, 16, 18, 45, 52, 58,
35, 51, and 31, in this order. More significantly, our data reveal that 25/80 (31.2%) of
cancer cases are positive for high-risk HPVs as well as EBV, and their co-presence is
associated with high/intermediate-grade squamous cell carcinomas. These data confirm
the co-presence of high-risk HPVs and EBV in HN cancers in the Syrian population of
the Middle East and demonstrate that their co-incidence is linked to a more aggressive
cancer phenotype. Thus, future studies are required to confirm these data and elucidate
the exact role of high-risk and EBV cooperation in human HN carcinogenesis.
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INTRODUCTION
Head and neck (HN) cancer is a broad term that incorporates epithelial malignancies located in the
paranasal sinuses, oral cavity, nasal cavity, pharynx, and larynx (1). HN cancer is one of the most
common among both male and female worldwide, with around 650,000 new cases and 330,000
deaths each year assessed by the World Health Organization (2); notably, most of these deaths
occur in developing countries (3). When it comes to cancer-related mortality, it is generally either
directly attributed to metastasis, as in tumor involvement of critical organs, or caused indirectly
due to therapeutic resistance and the adverse effect of treatment on human organs (4, 5).
Today, it is well-known that more than 20% of human cancers are estimated to be linked
with microorganism infections including oncoviruses infection especially high-risk human
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papillomaviruses (high-risk HPV) and Epstein–Barr virus (EBV)
(6–8). More specifically, it has been well-established that high-
risk HPV infections are critical etiological factors in the
development of human HN cancers, especially oral, as ∼40% of
oral cancer cases are positive for high-risk HPVs, particularly
types 16, 18, 31, 33, 35, 45, 52, and 58 worldwide including the
Middle East (ME) region (7, 9). Additionally, it was pointed
out that their presence is linked with vascular invasion and
lymph node metastases in different types of human carcinomas
including cervical and HN (10–12).
Likewise, EBV is a human gamma herpesvirus that commonly
infects more than 90% of the adult population (13). Persistent
infection with EBV can cause infectious mononucleosis, and its
latent state can lead to several types of human B-cell lymphomas
and certain solid cancers, especially nasopharyngeal (14–17);
additionally, EBV has been shown to be strongly associated with
undifferentiated nasopharyngeal carcinomas (NPCs). Several
studies have detected the presence of EBV in HN squamous
cell tumors implying its possible role in the development of
malignancies throughout the upper aerodigestive tract (7, 18, 19).
Moreover, it has been recently revealed that EBNA1 and LMP1
of EBV oncoproteins can enhance invasion of human cancer
cells via the induction of epithelial-to-mesenchymal transition
(EMT) (20, 21).
On the other hand, several recent studies revealed that high-
risk HPVs and EBV are co-present in human HN cancers
especially oral (22–24). Moreover, it has been reported that the
co-occurrence of high-risk HPVs and EBV in oral cancer is
associated with a significant increase in the invasiveness ability of
cancer cells (25). We recently demonstrated that the co-presence
of high-risk HPVs and EBV is linked to high/intermediate grade
in different types of human carcinomas including HN (5, 26, 27).
Thus, it is evident that the co-presence of high-risk HPVs and
EBV in high-grade human carcinomas could suggest a possible
cooperation between their oncoproteins; however, there are only
few studies regarding the co-presence of high-risk HPVs and
EBV in the ME region focusing only on NPCs.
Therefore, in this investigation, we assessed the presence
of high-risk HPVs and EBV and their association with tumor
phenotype in human HN cancer samples from Syria. Our
study pointed out that high-risk HPVs and EBV are present
in 43.7 and 51.2% of our samples, respectively, while co-
incidence of these oncoviruses is 32.2%. More significantly, we
noted that the co-incidence of these oncoviruses is associated
with high/intermediate-grade squamous cell carcinomas in the
majority of positive cases.
MATERIALS AND METHODS
High-Risk HPV and EBV Detection
Eighty formalin-fixed paraffin-embedded blocks of HN cancer
(57 larynx, 19 lower lip, 3 upper lip, and 1 nasopharynx) from
Syrian patients, 73 males and 7 females, with an average age
of 54.51 years were used. The samples were obtained from
the Pathology Department, Faculty of Medicine of Aleppo
University, Syria. Tissue blocks and data used in this report
were approved, in March 22, 2009, by the Ethics Committee
of the Faculty of Medicine of Aleppo University, # 2009-007,
Aleppo, Syria. One hundred nanograms of DNA was extracted
from each sample using Qiagen GmbH kit (Hilden, Germany).
These samples were analyzed for high-risk HPVs and EBV by
PCR using primers for E6/E7 genes of high-risk HPV types (16,
18, 31, 33, 35, 45, 51, 52, and 58) in addition to primers for LMP1
and EBNA1 genes of EBV; meanwhile, primers for the GAPDH
gene were utilized as an internal control (26, 28). This analysis
was achieved as illustrated earlier by our group (5, 26, 28).
Tissue Microarray
Tissue microarray (TMA) building was realized as elucidated
previously by our group (28, 29). Briefly, HN cancer samples
were inserted into a virgin paraffin TMA block using a non-
automated tissue arrayer (Beecher Instruments, Silver Spring,
MD) irrespective of pathological staging information. Three
TMA cores of 1.0mm in diameter were sampled from a cohort of
80 block tissue samples of Syrian HN cancer patients. Afterwards,
to verify the histological diagnosis, 4-µm sections were cut and
stained with hematoxylin and eosin (H&E). Then, slides of the
completed blocks were used for immunohistochemistry assay.
Immunohistochemistry
Immunohistochemical (IHC) procedures examining the
expression patterns of E6 and LMP1, of HPV and EBV, were
done using standard practices. Briefly, slides were deparaffinized
in graded alcohol, rehydrated, and boiled in 10mM citrate buffer
(pH 6.0) for antigen retrieval. Then, TMA slides were incubated
for 35min at 37◦C with primary monoclonal and polyclonal
antibodies for E6 of HPV and LMP1 of EBV (clones 1–4 and
clone C1P5 from Dako and Calbiochem, Canada, respectively)
using an automated immunostainer (Ventana Medical System,
Tuscon, AZ). Afterwards, staining procedures were achieved
according to the manufacturer’s recommendations as slides were
counterstained with hematoxylin prior to mounting. Negative
controls were achieved by omitting primary antibody for E6
and LMP1. Following immunohistochemistry, two independent
observers examined all TMA slides. The tumors were considered
positive for E6 and LMP1 oncoproteins if cancer cells exhibited
positivity ≥1% at any intensity (≥1+, scale 0–3+).
All TMAs also contained various cores representing positive
and negative controls (e.g., cervical carcinoma and lymphatic
tissues served as positive controls for HPV and EBV stains,
respectively; normal HN tissues and epithelium were used as
negative controls).
Statistical Analysis
Statistical assessments were achieved using IBM SPSS Statistics
(version 22; SPSS Inc., Chicago, IL, USA) and R. Data were
analyzed as non-parametric files. We used χ2-test with Yates
correction to explore the significance of the association between
tumor grade and the co-incidence of high-risk HPVs and EBV.
RESULTS
In order to classify the presence of high-risk HPVs and EBV in
human HN cancer tissues in the ME region, we explored the
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TABLE 1 | High-risk HPVs and EBV detection in human head and neck cancers.
Number of samples# HPVs+ EBV+ HPVs+/EBV+
Positive cases 35/80 41/80 25/80
(%)## (43.7) (51.2) (31.2)
The presence of HPVs and EBV was found in 35 (43.7%) and 41 (51.2%) of the 80 cancer
samples, respectively, while we observed that 25 (31.2%) of cancer cases are positive for
both high-risk HPVs and EBV. The presence of these oncoviruses was confirmed by PCR
and IHC using specific primers for E6/E7 and LMP1 as well as EBNA1 genes of high-risk
HPVs and EBV, in addition to monoclonal antibodies for E6 and LMP1, as illustrated in
the Materials and Methods section.
#The total number of samples examined in this study is 80.
##These twomethodologies, PCR and IHC, were used to detect the presences of high-risk
HPVs and EBV.
TABLE 2 | Presence of HPV types 16, 18, 31, 33, 35, 45, 51, 52, and 58 in
human HN cancer.
No. of cases High-risk HPVs
16 18 31 33 35 45 51 52 58
80 31/80 28/80 13/80 34/80 18/80 25/80 15/80 22/80 20/80
We note that HPV types 33, 16, 18, and 45 are the most common in HN cancer in the
Syrian population.
incidence of high-risk HPV types 16, 18, 31, 33, 35, 45, 51, 52,
and 58 in a cohort of 80 HN cancer specimens from the Syrian
population by PCR analysis, using specific primers for E6/E7 and
LMP1 as well as EBNA1 genes of HPVs and EBV, respectively
(5, 26, 28). Our data revealed that 35 (43.7%) and 41 (51.2%) of
the 80 cancer samples are positive for high-risk HPVs and EBV,
respectively (Table 1), and all of HPVs-positive specimens are
co-infected with more than one HPV type. Regarding high-risk
HPVs genotyping in these samples, our results pointed out that
the most prevalent high-risk HPVs among the positive samples
are types 33 (34/80), 16 (31/80), 18 (28/80), 45 (25/80), 52 (22/80),
58 (21/80), 35 (18/80), 51 (15/80), and 31 (13/80), as shown in
Table 2.
Next, we investigated the co-presence of high-risk HPVs
and EBV in our HN cancer samples by IHC and PCR analysis
using monoclonal antibodies, for E6 and LMP1, as well as
specific primers for these oncoproteins/genes, respectively; we
found that 25 (31.2%) of the 80 cancer cases are positive
for both high-risk HPVs and EBV with P < 0.001 (Table 1).
Furthermore, we examined the relation between the co-presence
of these oncoviruses and tumor grade in these samples. Our data
revealed that the co-expression of E6 and LMP1 oncoproteins
of high-risk HPVs and EBV, respectively, in the majority of
cases (88%) is associated with high/intermediate (G3/G2)-grade
invasive carcinoma form in comparison with high-risk HPVs+
or EBV+ alone cases or HPVs/EBV-negative cases, which are
4/10 (40%), 5/16 (31.2%), and 3/29 (10.2%) with P = 0.00328,
0.00018, and <0.001, respectively (Table 3 and Figures 1, 2),
while it is important to highlight that cancer phenotype in the
HPV+/EBV+ was not linked to a specific HPV type since all our
positive cases were infected with more than one type of high-
risk HPVs. Finally, normal HN tissues and epithelial cells, which
TABLE 3 | High-risk HPVs and EBV status in relation to tumor grade in HN cancer
samples.
EBV/HPVs
status
EBV+/HPVs+
(%)
EBV+/HPVs−
(%)
EBV−/HPVs+
(%)
EBV−/HPVs−
(%)
TUMOR GRADE
High 5 (20.0) 1 (10.0) 2 (12.5) 1 (3.4)
Intermediate 17 (68.0) 3 (30.0) 3 (18.7) 2 (6.8)
Low 3 (12.0) 6 (60.0) 11 (68.7) 26 (89.6)
Number of
samples#
25 (31.2) 10 (12.5) 16 (20.0) 29 (36.2)
We notice that 88% of HPVs- and EBV-positive cases are high/intermediate-grade
carcinomas in comparison with EBV+/HPV−, EBV−/HPV+, and EBV−/HPV−, which are
40, 31.2, and 10.2% with a P-value of 0.00328, 0.00018, and <0.001, respectively.
#The total number of samples examined in this study is 80.
Values inside parentheses denote percentage.
FIGURE 1 | High-grade (Grade 3), non-keratinizing squamous cell carcinomas
with basaloid appearance. Tumor cells were diffusely (>75%) and strongly (2+
and 3+ intensity on the scale 0–3) positive for both HPV (E6, upper images)
and EBV (LMP1 protein) (lower images). The left-sided images are captured at
4× magnification, while the right-side ones are at 10× magnification (Olympus
BX53). Expression of both proteins was assessed by immunohistochemistry
using a semiquantitative approach.
served as controls, were shown to be negative for both high-risk
HPVs as well as EBV.
DISCUSSION
In this investigation, we explored, for the first time, the
incidence/co-incidence of high-risk HPVs and EBV in human
HN cancer and the association of their co-presence with tumor
grade in Syria, which can also be considered the first study of
this type in the ME region. We report that high-risk HPVs and
EBV are present in 43.7 and 51.2%, respectively, in our Syrian
samples, and the most frequent HPV types in HN cancer in
Syria are 33, 16, 18, 45, 52, 58, 35, 51, and 31, correspondingly.
Meanwhile, our data pointed out that 31.2% of the samples are
positive for both high-risk HPVs and EBV. More significantly,
we report that the co-presence of these oncoviruses is associated
with high/intermediate tumor grade in 88% of the samples in
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FIGURE 2 | A case of moderately differentiated (Grade 2) squamous cell
carcinoma exhibiting co-expression of E6 (upper images) and LMP1 (lower
images) oncoproteins of HPV and EBV, respectively. Left-sided images are
captured at 4× magnification, while the right-sided ones are at 10×
magnification (Olympus BX53). Note that the expression of E6 protein was
observed in >90% of cancer cells while LMP1 protein was expressed in
∼70% of cancer cells. Expression of both oncoproteins was assessed by
immunohistochemistry using a semiquantitative approach.
comparison to HPVs or EBV-positive alone and HPVs/EBV-
negative samples. Regarding the most common HPV types
in the Syrian population, the present data concur with our
previous studies onHPVs in different types of human carcinomas
including cervical and breast in Syria where we found that HPV
type 33 is the most frequent in these cancer tissues. In this
context, HPV type 33 was reported to be the most common in
breast cancer in Turkey (30). Herein, it is important to highlight
that the Syrian samples were collected from Aleppo province,
which is located in the northern part of the country bordering
Turkey. Accordingly, our data confirm that specific types of high-
risk HPV infection, in human cancers, are related to certain
geographic locations, as it was demonstrated by a large number
of investigations worldwide (7, 31–36).
Concerning the co-presence of HPVs and EBV in HN cancer
in the ME region, Tatli Dogan et al. (37) published a study
regarding the incidence of HPVs and EBV in NPCs in Turkey,
they found that 72 of their 82 samples are positive for EBV
and only one case revealed positive for HPVs; meanwhile, they
reported that the highest rate of EBV positivity correspond with
undifferentiated NPCs. However, and in agreement with our
investigation, one report fromNorth Africa assessed the presence
and co-presence of high-risk HPVs and EBV in 70 cases of NPCs
from the Moroccan population (38). Their study revealed that
24 of the samples are positive for high-risk HPVs, and the most
frequent HPV types are 31, 59, 16, 18, 33, and 35. They found
that all their cancer cases are positive for EBV. Consequently,
24 (34%) Moroccan samples were positive for both high-risk
HPVs and EBV, which are in their majority NPCs grade III and
II. It is important to highlight that the Turkish and Moroccan
studies in addition to another investigation from Iran with only
20 cancer cases (39) focused only on the co-presence of HPVs and
EBV in NPCs; therefore, our investigation can be considered the
first study regarding the co-presence of these oncoviruses in HN
cancer in the ME region since our samples include tissues from
several HN locations.
On the other hand, in 2012, Jalouli et al. (40) examined the
incidence and co-incidence of high-risk HPVs and EBV in 155
oral squamous cell carcinomas (OSCCs) from eight different
countries from Europe, Asia, Africa, and North America with
a limited number of cases ∼20 cancer cases from each country
including Sudan and Yemen from the ME region. They found
that 35 and 55% of the samples are positive for HPVs and EBV,
respectively. They reported that HPVs and EBV are co-present
in 21% of all OSCCs. However, no clear conclusions can be
drawn from this study due to the limited number of cancer cases
from participant countries. Meanwhile, there are two recently
published investigations from Europe regarding the presence of
HPVs and EBV in human oral cancer; one from Poland showed
that HPVs and EBV are co-present in 34.1% of cancer cases in
comparison with HPV and EBV infections alone, which are 28.1
and 54.7%, respectively (23). In the second study from Finland,
the authors reported that the co-incidence of HPV and EBV
is 14% in the population of Finland (41). In comparison, our
study focused on the presence/co-presence of HPVs and EBV
in HN cancer in Syria with an acceptable number of samples,
which allowed us to make an adequate conclusion about these
oncoviruses in HN cancer in this country, revealing that 31.2%
of the samples are HPVs+/EBV+, which is comparable with the
study published from Poland.
The co-presence of high-risk HPVs and EBV and their
association with tumor phenotype in HN cancer is clearly
demonstrated in our present study regardless of HPV type
since all our HPV/EBV-positive cases are infected with more
than one HPV virus strain. Our findings are in agreement
with several investigations worldwide, including three from
our group in addition to the Turkish and Moroccan studies;
data of these reports pointed out that the co-presence of
HPVs and EBV is associated with high-grade carcinomas in
addition to positive axillary lymph nodes (5, 23, 25–27, 42,
43). Indeed, it has been reported that prevalence of poorly
differentiated tumors is four times more frequent in HPV/EBV
co-infection in comparison with EBV or HPV infection alone
in oral cancer samples from Poland (23); in addition, the
study pointed out that there is a significant correlation
between tumor dimensions in co-infected patients compared
with single infection. However, a recent investigation in NPCs
reported that 5-year overall survival is significantly higher
in HPV/EBV-positive patients in comparison with HPV/EBV-
negative ones (41). Well, this could be due to radiation
sensitivity as demonstrated by several investigations. Actually,
earlier studies in HPV-positive cases of HNSCC found that
the virus takes control of the cellular machinery for DNA
repair, altering cell cycle distribution and causing hypoxia
during radiation treatment (44, 45). On the other hand,
numerous studies on the alteration of radiation response by
EBV reported that LMP-1 blocks DNA repair by suppressing
the phosphorylation and activity of DNA-dependent protein
kinase, a key enzyme of non-homologous end-joining pathway
in NPCs, and by repressing ATM, which ultimately modulates
resistance of ionizing radiation-induced apoptotic cell death
(46).
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Apropos the mechanism of HPVs and EBV interaction, based
on the fact that high-risk HPVs and EBV oncoproteins share
different downstream pathways, we assumed that oncoproteins
(E5, E6/E7, LMP1, and EBNA1) of these oncoviruses can
cooperate in the initiation and/or progression of several types
of human carcinomas where the EMT event can play a crucial
role in this procedure (47). Indeed, earlier investigations showed
that E5 and E6/E7 oncoproteins of high-risk HPVs can enhance
cell invasion and cancer progression via the induction of
EMT in several types of human cancers including cervical
and oral as well as NPCs (48–53). On the other hand, it has
been reported by several investigations that LMP1, LMP2A,
EBNA3C, and EBNA1 oncoproteins of EBV can enhance cancer
progression via the modulation of EMT in human carcinomas
including NPCs (20, 53–56). Meanwhile, our preliminary data
showed that E6/E7 of HPV type 16 can cooperate with LMP1
of EBV to enhance EMT progression and consequently cell
motility via the activation (phosphorylation) of Erk1/Erk2 and β-
catenin (in preparation). Nevertheless, further studies are needed
to elucidate the complete pathogenesis and role of the co-
incidence of high-risk HPVs and EBV in human carcinomas
including HN, especially since HPVs and EBV vaccines are
currently available and under clinical trial, respectively (57–
59). This is a key step, which could possibly limit HPV
and EBV infection and their associated cancers including
HN malignancy initiation and development to a metastatic
form, thus diminishing cancer-related mortalities especially in
developing countries where oncoviruses-associated cancers are
still considered major causes of death among both males and
females in these countries.
Lastly, with regard to the number of specimens that we were
able to amass from Aleppo, Syria, it is essential to confirm our
data using a larger number of samples from different areas in this
country and in combination with numerous investigations from
the ME in general.
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